Therapeutic idiotype vaccines in B lymphoproliferative diseases

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 959-963

  Coscia, Marta ^a,b,c   Kwak, Larry W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Antitumour vaccination; B cell lymphoma; Idiotype vaccines; Multiple myeloma

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; TUMOR ANTIGEN;

B CELL LYMPHOMA; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MOLECULAR RECOGNITION; REVIEW; VACCINATION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MICE; MULTIPLE MYELOMA; VACCINES, DNA;

EID: 3042545944     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.959     Document Type: Review

References (42)

1. LYNCH RG, CRAFF RG, SIRISINHA S, SIMMS ES, EISEN HN: Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA (1972) 69:1540-1544.
2. JORGENSEN T, GAUDERNACK G, HANNESTAD K: Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand. J. Immunol. (1980) 11(1):29-35.
3. DALEY MJ, GEBEL HM, LYNCH RG: Idiotype-specific transplantation resistance to MOPC-315: abrogation by postimmunization thymectomy. J. Immunol. (1978) 120(5):1620-1624.
4. BRIDGES SH: Participation of the humoral immune system in the myeloma-specific transplantation resistance. J. Immunol. (1978) 121(2):479-483.
5. FREEDMAN PM, AUTRY JR, TOKUDA S, WILLIAMS RC JR. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. J. Natl. Cancer Inst. (1976) 56(4):735-740.
6. SUGAI S, PALMER DW, TALAL N, WITZ IP: Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J. Exp. Med. (1974) 140(6):1547-1558.
7. STEVENSON FK, GORDON J: Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J. Immunol. (1983) 130(2):970-973.
8. GEORGE AJ, TUTT AL, STEVENSON FK: Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. (1987) 138(2):628-634.
9. KAMINSKI MS, KITAMURA K, MALONEY DG, LEVY R: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. (1987) 138(4):1289-1296.
10. KWAK LW, YOUNG HA, PENNINGTON RW, WEEKS SD: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA (1996) 93:10972-10977.
11. KWAK LW, CAMPBELL MJ, CZERWINSKI DK, HART S, MILLER RA, LEVY R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. (1992) 327:1209-1215.
12. HSU FJ, CASPAR CB, CZERWINSKI D et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood (1997) 89:3129-3135.
13. BENDANDI M, GOCKE CD, KOBRIN CB et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med .(1999) 5:1171-1177.
14. NEELAPU SS, GAUSE BL, NIKCEVICH DA et al.: Phase III randomized trial of patient-specific vaccination for previously untreated follicular lymphoma patients in first complete remission: protocol summary and interim report. Clin. Lymphoma (2004) (In Press).
15. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
16. TIMMERMAN JM, CZERWINSKI DK, DAVIS TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 99(5):1517-1526.
17. NEELAPU SS, BASKAR S, GAUSE BL et al.: Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. (2004) (Manuscript submitted).
18. DIANZANI U, PILERI A, BOCCADORO M et al.: Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood (1988) 72(3):1064-1068.
19. YI Q, OSTERBORG A, BERGENBRANT S, MELLSTEDT H, HOLM G, LEFVERT AK: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood (1995) 86(8):3043-3049.
20. YI Q, ERIKSSON I, HE W, HOLM G, MELLSTEDT H, OSTERBORG A: Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets. Br. J. Haematol. (1997) 96(2):338-345.
21. BOGEN B, MALISSEN B, HAAS W: Idiotype-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class III molecules. Eur. J. Immunol. (1986) 16(11):1373-1378.
22. LI Y, BENDANDI M, DENG Y et al.: Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood (2000) 96:2828-2833.
23. HAYASHI T, HIDESHIMA T, AKIYAMA M et al.: Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood (2003) 102(4):1435-1442.
24. BERGENBRANT S, YI Q, OSTERBORG A et al.: Modulation of antiidiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br. J. Haematol. (1996) 92(4): 840-846.
25. OSTERBORG A, YI Q, HENRIKSSON L. et al.: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood (1998) 91(7):2459-2466.
26. MASSAIA M, BORRIONE P, BATTAGLIO S et al.: Id vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood (1999) 94:673-683.
27. COSCIA M, MARIANI S, BATTAGLIO S et al.: Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia (2004) 18(1):139-145.
28. REICHARDT VL, OKADA CY, LISO A et al.: Id vaccination using denctritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood (1999) 93(7):2411-2419.
29. YI Q, DESIKAN R, BARLOGIE B, MUNSHI N: Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. J. Haematol. (2002) 117:297-305.
30. TITZER S, CHRISTENSEN O, MANZKE O et al.: Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. (2000) 108:805-816.
31. GONG J, KOIDO S, CHEN D et al.: Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma ceus is potentiated by interleukin 12. Blood (2002) 99:2512-2517.
32. RASMUSSEN T, HANSSON L, OSTERBORG A, JOHNSEN HE, MELLSTEDT H: Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood (2003) 101(11):4607-4610.
33. ANDERSON KC, KYLE RA, DALTON WS et al.: Multiple myeloma: new insights and therapeutic approaches. Hematology (American Society of Hematology Education Program) (2000):146-165.
34. KAY NE, LEONG TL, BONE N et al.: Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group Phase III trial for newly diagnosed multiple myeloma patients. Blood (2001) 98(1):23-28.
35. KAY NE, LEONG T, KYLE RA et al.: Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group Phase III E9486 clinical trial. Blood (1997) 90(1):340-345.
36. MASSAIA M, BORRIONE P, ATTISANO C et al.: Dysregulated Fas and Bd-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood (1995) 85(12):3679-3687.
37. RATTA M, FAGNONI F, CURTI A et al.: Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 100(1):230-237.
38. KWAK LW, NEELAPU S, BISHOP MR: Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin. Oncol. (2004) 31(1):37-46.
39. KING CA, SPELLERBERG MB, ZHU D et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. (1998) 4(11):1281-1286.
40. SAVELYEVA N, MUNDAY R, SPELLERBERG MB, LOMONOSSOFF GP, STEVENSON FK: Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat. Biotechnol. (2001) 19(8):760-764.
41. BIRAGYN A, SURENHU M, YANG D et al.: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. (2001) 167(11):6644-6653.
42. BIRAGYN A, TANI K, GRIMM MC, WEEKS S, KWAK LW: Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. (1999) 17(3):253-258.